December 17, 2024 11:05 AM EST

Health tech investing during Trump 2.0

Lydia Ramsey Pflanzer

Deputy Editor

With the presidential inauguration roughly a month away, we checked in with some top health tech investors about what they’re predicting. Most don’t expect huge …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Health tech investing during Trump 2.0

Lydia Ramsey Pflanzer

Deputy Editor

Sign up to read this article for free.

Major PBM reforms feature in Congress' year-end spending bill

Chicago’s biotech scene is growing up. What’s fueling it?

In surprise move, FDA's No. 2 Bumpus to leave agency at end of 2024

Pfizer’s message to investors: The ship is steadying in 2025 (even if Washington is turbulent)

Jazz Pharmaceuticals CEO and co-founder Bruce Cozadd is retiring

UCB, Novartis say a Phase 2a Parkinson's study failed

Health tech in­vest­ing dur­ing Trump 2.0

Lydia Ramsey Pflanzer

Deputy Editor

Sign up to read this article for free.

more like this

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

Chica­go’s biotech scene is grow­ing up. What’s fu­el­ing it?

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Pfiz­er’s mes­sage to in­vestors: The ship is steady­ing in 2025 (even if Wash­ing­ton is tur­bu­lent)

Jazz Phar­ma­ceu­ti­cals CEO and co-founder Bruce Cozadd is re­tir­ing

UCB, No­var­tis say a Phase 2a Parkin­son's study failed

Health tech investing during Trump 2.0

Major PBM reforms feature in Congress' year-end spending bill

Chicago’s biotech scene is growing up. What’s fueling it?

In surprise move, FDA's No. 2 Bumpus to leave agency at end of 2024

Pfizer’s message to investors: The ship is steadying in 2025 (even if Washington is turbulent)

Jazz Pharmaceuticals CEO and co-founder Bruce Cozadd is retiring

UCB, Novartis say a Phase 2a Parkinson's study failed